Fatty acid synthase (FASN) is a large enzyme responsible for building the saturated fat palmitate from smaller molecular building blocks, and its fingerprints show up in a remarkably wide range of diseases. In healthy tissues, FASN operates mostly in the liver, adipose tissue, and lactating breast, quietly producing fatty acids when the body has excess energy to store. But when FASN activity goes haywire, the consequences ripple across cancer biology, liver disease, brain development, viral infections, and even aging. Understanding this single enzyme opens a window into how the body’s fat-making machinery intersects with some of the most pressing problems in modern medicine.
What FASN Actually Does
FASN is a large protein that works as a pair of identical subunits locked together. Each subunit contains multiple catalytic sites that perform a series of chemical reactions in sequence, assembling small two-carbon units into the 16-carbon saturated fatty acid palmitate.1PubMed Central. Human fatty acid synthase: structure and substrate selectivity of the thioesterase domain Think of it like a tiny assembly line housed inside one protein: raw materials enter at one end, and a finished fatty acid rolls off the other. That palmitate then gets modified into longer or unsaturated fats, incorporated into cell membranes, or stored as energy reserves.
This type of enzyme architecture, where one large polypeptide handles the entire synthesis pathway, is sometimes called a type I fatty acid synthase. Bacteria, by contrast, use a completely different system: a collection of separate, smaller enzymes that each handle one step. That structural difference matters for drug design, because a compound targeting one system may not affect the other, which is one reason antibiotics aimed at bacterial fat synthesis don’t poison human cells.
Under normal conditions, the body tightly controls when and how much FASN is active. Insulin and feeding trigger a set of signaling proteins that ramp up FASN production in the liver and fat tissue.2PubMed Central. Insulin signaling in fatty acid and fat synthesis: a transcriptional perspective When you eat a carbohydrate-rich meal, your body essentially flips a switch that tells liver cells to start converting excess sugar into fat for storage. FASN is the workhorse of that conversion. Beyond these well-known signals, researchers have found that a sugar-based chemical tag called O-GlcNAcylation also regulates FASN’s stability and activity. Specific sites on the FASN protein need this tag for the enzyme to fold correctly, sit in the right part of the cell, and stay active.3Journal of Biological Chemistry. O-GlcNAcylation of fatty acid synthase is required for its proper subcellular localization, expression level, and activity Lose the tag at a critical spot, and the enzyme falls apart.
How FASN Fuels Cancer
Most healthy adult cells get the fats they need by pulling them from the bloodstream. Cancer cells often take a different approach: they crank up their own internal fat production, making them far less dependent on outside supply. FASN sits at the center of this shift. Across a wide range of tumor types, FASN is overexpressed and functions as a central regulator of lipid metabolism that supports tumor growth and survival.4PubMed Central. Fatty Acid Synthase: An Emerging Target in Cancer
Why would a tumor bother making its own fat? The answer goes beyond simple energy storage. The palmitate that FASN produces gets woven into cell membranes, and a membrane built with a high proportion of saturated fatty acids has different physical properties. It becomes more rigid and more resistant to damage. Those altered membranes allow tumor cells to organize signaling complexes on their surface more efficiently, promoting continued proliferation. They also make tumor cells harder to kill with conventional chemotherapy, because the dense, saturated membranes are less susceptible to the oxidative damage that many cancer drugs inflict.5PubMed. Fatty acid synthase – Modern tumor cell biology insights into a classical oncology target In other words, FASN doesn’t just feed tumors; it armors them.
The HER2 Feedback Loop
One of the more striking discoveries in FASN cancer biology involves its relationship with HER2, a growth receptor that drives aggressive forms of breast cancer and certain other tumors. In HER2-overexpressing breast cancer cells, the HER2 protein physically interacts with FASN and triggers its phosphorylation, which increases FASN’s enzymatic activity. Blocking that phosphorylation with the drug lapatinib, or with the FASN inhibitor C75, suppressed both FASN activity and the invasive behavior of the cancer cells.6PubMed Central. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells
The relationship runs in both directions. Research in bone cancer cells has shown that HER2 boosts FASN levels, and when you inhibit FASN, HER2 and its activated form both drop.7PubMed Central. Interaction between fatty acid synthase and human epidermal growth receptor 2 (HER2) in osteosarcoma cells This positive feedback loop means that the two proteins prop each other up: HER2 drives FASN, and FASN sustains HER2. Disrupting either side of the loop weakens both. This mutual dependency is one reason researchers see FASN inhibition as a potential way to tackle HER2-driven cancers that have stopped responding to standard HER2-targeted therapies.
FASN Inhibitors as Cancer Drugs
Scientists first identified FASN as a cancer target more than two decades ago, but early drug candidates had serious problems. Compounds like cerulenin and C75 worked in lab dishes but caused side effects in animals, including dramatic appetite suppression and weight loss, that made them impractical for patients. Interest faded for a while.
The field was revitalized by denifanstat (originally called TVB-2640), the first FASN inhibitor designed from the ground up to be selective enough and well-tolerated enough for human use. Denifanstat has shown encouraging antitumor activity in preclinical models and in early-phase clinical trials.8PubMed. Targeting cancer metabolism: Therapeutic potential of the fatty acid synthase (FASN) inhibitors It is currently being studied across several phase II trials for different tumor types.9PubMed Central. Fatty acid synthase (FASN) signalome: A molecular guide for precision oncology
One of the more closely watched applications is in glioblastoma, the most lethal common brain tumor. Glioblastoma cells are known to upregulate FASN to feed their demand for new membranes. A phase II trial combined denifanstat with bevacizumab (the blood-vessel-blocking antibody already used in brain cancer) in patients with recurrent high-grade brain tumors.10Clinical Cancer Research. Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma The logic is compelling: starve the tumor of the fats it needs while simultaneously cutting off its blood supply. Results from that and similar trials will determine whether FASN inhibition finally makes the leap from the lab bench to the oncology clinic.
Fatty Liver Disease
Cancer isn’t the only disease where FASN matters. Non-alcoholic fatty liver disease, in which fat accumulates in liver cells without heavy alcohol use, has become one of the most common liver conditions worldwide. FASN catalyzes the final step in converting excess carbohydrate into fat within the liver, so it stands to reason that overactive FASN would contribute to the problem.
Studies bear this out, with a nuance. In a study of over 100 human liver samples, FASN levels were significantly higher in livers with simple fat accumulation (steatosis) but were not elevated in livers that had progressed to the inflammatory stage known as NASH.11PubMed Central. Expression of fatty acid synthase in nonalcoholic fatty liver disease The same pattern held in mouse models. This suggests that FASN is a driver of the early fat-loading phase. Once inflammation takes over, other mechanisms dominate, and FASN’s role becomes less clear-cut.
That early-phase importance has made FASN an attractive drug target for fatty liver disease. In animal models, the natural FASN inhibitor platensimycin reduced liver fat and improved insulin sensitivity in mice fed a high-fructose diet, and lowered blood sugar in diabetic mice.12PubMed Central. Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes In humans, a different FASN inhibitor called FT-4101 reduced liver fat and blocked new fat production in the liver over a 12-week trial in obese people with fatty liver disease.13PubMed Central. Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials The fact that different inhibitors in different species converge on the same result lends credibility to the idea that dialing down FASN can meaningfully reduce liver fat.
Omega-3 fatty acids, long promoted for metabolic health, appear to work partly through this same pathway. Research suggests that omega-3s can suppress FASN expression in the liver, shifting the balance from fat storage toward fat burning. The mechanism seems to involve a signaling chain where omega-3s boost the activity of a protein called SIRT1, which in turn dials down the transcription factors that drive FASN production.
FASN and the Developing Brain
While too much FASN activity in the liver causes trouble, the brain depends on it. Neural stem cells in the adult mouse brain are highly active producers of fat via FASN, and when researchers deleted the FASN gene specifically in those stem cells, adult neurogenesis was impaired.14PubMed Central. Metabolic control of adult neural stem cell activity by Fasn-dependent lipogenesis The brain, after all, is the fattiest organ in the body, and its cells require a constant local supply of specific lipids to build and maintain their elaborate membranes.
The stakes are even higher during embryonic development. Deleting FASN in the developing mouse forebrain caused severe microcephaly because the radial glia cells that serve as scaffolding for brain construction lost their normal orientation and stopped dividing properly. The same effect was confirmed in human brain organoids grown from stem cells, indicating a conserved role across species.15PubMed Central. FASN-dependent de novo lipogenesis is required for brain development These findings raise a practical concern: any drug that strongly inhibits FASN would need to be kept away from developing fetuses and potentially from young children whose brains are still maturing. For cancer patients of reproductive age, this is a real design constraint for FASN-targeting therapies.
When Viruses Commandeer the Fat Factory
FASN is not only a target for the body’s own diseases. A growing number of viruses have been found to hijack FASN to support their own replication. The fatty acid palmitate, FASN’s main product, is useful to viruses in several ways: it can be used to build the lipid envelopes that wrap around new viral particles, it can be burned for energy to power viral assembly, and it can be attached to viral or host proteins to redirect them to the right part of the cell.16PubMed Central. Mammalian fatty acid synthase: a commonly used viral host dependency factor and a putative target for host-targeted broad-spectrum antiviral therapeutic development
Dengue virus provides a well-studied example. The virus’s nonstructural protein 3 physically relocates FASN from its usual position in the cell to the sites where the virus assembles its replication machinery, effectively conscripting the enzyme into service.17PubMed Central. Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis By boosting fat production right where it needs it, dengue creates the lipid-rich environment its replication complexes require.
Because FASN is a host protein rather than a viral one, it doesn’t mutate under selective pressure the way viral targets do. This makes it an appealing target for broad-spectrum antivirals. A drug that reduces FASN activity could, in principle, hamper the replication of multiple unrelated viruses that share this dependency. The challenge, as with cancer, is doing so without causing too much collateral damage to the host’s own fat metabolism.
Appetite Suppression and the Hypothalamus
Some of the earliest and most dramatic observations about FASN inhibition had nothing to do with tumors or liver fat. When researchers gave mice the FASN inhibitors cerulenin or C75, the animals almost completely stopped eating and lost substantial weight. The compound C75 suppressed the hunger-promoting signal neuropeptide Y in the hypothalamus and acted independently of leptin, the hormone usually credited with long-term appetite regulation.18PubMed. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors
Closer investigation revealed a two-phase mechanism. Within two hours of receiving C75, mice showed activation of brainstem neurons involved in acute feeding suppression. Over the following hours, the drug reshaped the hypothalamic appetite circuit by suppressing hunger-promoting signals and boosting satiety signals.19PubMed Central. Effect of the anorectic fatty acid synthase inhibitor C75 on neuronal activity in the hypothalamus and brainstem The resulting appetite suppression was nearly total and lasted at least 24 hours.
This was both exciting and alarming. On one hand, it suggested a potential avenue for treating obesity. On the other, it meant that any systemically administered FASN inhibitor would likely cause serious appetite and weight side effects. The development of newer, more selective inhibitors like denifanstat has been partly driven by the need to block FASN in target tissues (tumors or liver) without triggering the kind of dramatic appetite shutdown seen with cruder compounds. Whether this balance can be achieved in practice remains an active area of clinical investigation.
FASN in Skin Biology
The skin is another organ where FASN plays a role that often gets overlooked. Epidermal cells produce FASN as they differentiate and move toward the skin surface, with the highest activity found in the upper layers of the epidermis. FASN is also strongly expressed in sebaceous glands, which produce the oily sebum that coats hair and skin, and in sweat glands, which appear capable of generating their own fatty acids. In the lower layers of the epidermis, FASN activity seems to be regulated more by local inflammatory signals than by the circulating hormones that control it in the liver.
This local regulation matters because it means skin FASN can ramp up or down in response to injury, infection, or chronic inflammation without waiting for whole-body metabolic signals. Conditions like psoriasis and acne, which involve both inflammation and abnormal lipid production in the skin, likely intersect with FASN activity, though the therapeutic implications haven’t been as thoroughly explored as in cancer or liver disease.
Aging and Cellular Senescence
As the body ages, cells accumulate in a state called senescence: they stop dividing but refuse to die, instead pumping out inflammatory molecules that damage surrounding tissue. This buildup of senescent cells is considered one of the hallmarks of aging. Research has found that FASN expression increases in the livers of aged mice and is associated with higher levels of senescence markers. When the FASN inhibitor C75 was applied, it reduced key inflammatory signals that senescent cells secrete, possibly by driving down levels of the p53 protein that regulates this inflammatory output.20Cell Death & Disease. FASN activity is important for the initial stages of the induction of senescence
The idea that blocking FASN could reduce the burden of senescent cells and delay age-related disease is intriguing but very preliminary. Most of the evidence comes from cell culture and mouse tissue. Whether FASN inhibition could serve as a senolytic or senomorphic strategy in humans, without causing the appetite and metabolic side effects described earlier, is an open question that hasn’t progressed to clinical testing for aging specifically.
Imaging FASN Activity to Detect Cancer
Because tumors with high FASN activity gobble up building blocks for fat synthesis, researchers have exploited this appetite for diagnostic imaging. A radioactive form of acetate, the two-carbon molecule that feeds into the FASN pathway, can be used as a tracer in PET scans. In prostate cancer, studies have confirmed that the uptake of this tracer tracks with FASN expression in the tumor, offering a potential non-invasive way to identify which tumors are most dependent on fat synthesis.21Journal of Nuclear Medicine. 1-11C-Acetate as a PET Radiopharmaceutical for Imaging Fatty Acid Synthase Expression in Prostate Cancer
This matters because not all cancers rely on FASN equally. If a patient’s tumor lights up on an acetate PET scan, they might be a strong candidate for FASN-targeted therapy. If it doesn’t, that therapy would likely be wasted on them. The ability to match patients to treatments based on their tumor’s metabolic profile, rather than just its tissue of origin, is exactly the kind of precision oncology tool that modern cancer medicine is pushing toward. Acetate PET isn’t widely used yet for this purpose, but the concept is an elegant example of turning basic biochemistry into a clinical decision-making aid.
Bacterial Versus Mammalian Fat Synthesis
The structural difference between mammalian and bacterial fatty acid synthase systems has implications beyond basic biology. In mammals, FASN is a single enormous protein of roughly 260 kilodaltons per subunit, with all catalytic activities built into one polypeptide chain. Bacteria use a completely different architecture: each step in the pathway is carried out by a separate, independently encoded enzyme. This dissociated system, called type II fatty acid synthase, is distinct enough from the human version that drugs can be designed to hit one without affecting the other.22Journal of Lipid Research. Bacterial fatty acid synthesis: a target for antibacterial drug discovery
Several existing antibiotics, including the tuberculosis drug isoniazid, already work by targeting bacterial fatty acid synthesis enzymes. The structural divergence between type I and type II systems is what makes these drugs safe for human use. Conversely, a FASN inhibitor designed to treat cancer or fatty liver disease in humans would not be expected to work as an antibiotic, because it targets a fundamentally different protein architecture. This clean separation between the two systems is something of a gift for pharmacology: it allows researchers to pursue anti-infective and anti-metabolic drug programs targeting fat synthesis without worrying about cross-reactivity between the two kingdoms of life.